Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Aug 15, 2021; 13(8): 772-798
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.772
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.772
Table 1 Common terminology criteria for adverse events
| Grade | Diarrhea | Colitis |
| 1 | Increase of < 4 stools/d over baseline | Asymptomatic |
| 2 | Increase of > 4-6 stools/d | Abdominal pain, mucus, and blood in stools |
| 3 | Increase of ≥ 7 stools/d, incontinence, and limiting self-care activity of daily living | Severe pain, fever, peritoneal signs, ileus |
| 4 | Life-threatening consequences (hemodynamic collapse) | Life-threatening consequences (perforation, ischemia, necrosis, bleeding, and toxic megacolon) |
| 5 | Death | Death |
- Citation: Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(8): 772-798
- URL: https://www.wjgnet.com/1948-5204/full/v13/i8/772.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i8.772